(UroToday.com) Tivozanib is a potent and highly selective VEGF receptor tyrosine kinase inhibitor with a long half-life that is an effective treatment option for patients with previously treated metastatic renal cell carcinoma (RCC). In the phase 3 TIVO-3 trial, tivozanib demonstrated favorable tolerability and statistically significant improvement in progression free survival (PFS; median PFS 5.6 versus 3.9 months; HR 0.73, 95% CI 0.56-0.94) and overall response rate (18% versus 8%) compared with sorafenib in patients with metastatic RCC as assessed by an independent radiology review.1 Based on these findings tivozanib was approved by the FDA for the treatment of patients with relapsed or refractory advanced RCC following two or more prior systemic therapies. At the 2021 ASCO virtual annual meeting, Dr. Elena Verzoni and colleagues presented long-term durability of response data, as well as updated overall survival outcomes among patients in the TIVO-3 trial.